Fusion Pharmaceuticals Inc. Interest Paid, Excluding Capitalized Interest, Operating Activities
Fusion Pharmaceuticals Inc. reported Interest Paid, Excluding Capitalized Interest, Operating Activities of $1.63 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:InterestPaidNet · last filed 2024-05-07
- Fusion Pharmaceuticals Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2024-03-31 was $1.63M, a 48.63% increase year-over-year.
- Fusion Pharmaceuticals Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2023-12-31 was $1.19M, a 14.51% increase year-over-year.
- Fusion Pharmaceuticals Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2023-09-30 was $1.19M, a 257.23% increase year-over-year.
- Fusion Pharmaceuticals Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2023-06-30 was $1.15M.
- Fusion Pharmaceuticals Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2023 was $4.62M, a 191.55% increase from fiscal 2022.
- Fusion Pharmaceuticals Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2022 was $1.59M.
| Period end | Interest Paid, Excluding Capitalized Interest, Operating Activities 3 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 6 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 9 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 12 month |
|---|---|---|---|---|
| 2024-03-31 | $1.63M 10-Q · filed 2024-05-07 | $2.82M derived: sum of 2 quarters · filed 2024-05-07 | $4.01M derived: sum of 3 quarters · filed 2024-05-07 | $5.16M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $2.38M derived: sum of 2 quarters · filed 2024-03-20 | $3.53M derived: sum of 3 quarters · filed 2024-03-20 | $4.62M 10-K · filed 2024-03-20 |
| 2023-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.34M derived: sum of 2 quarters · filed 2023-11-07 | $3.43M 10-Q · filed 2023-11-07 | $4.47M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.25M 10-Q · filed 2023-08-08 | $3.29M derived: sum of 3 quarters · filed 2024-05-07 | $3.62M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-07 | $2.14M derived: sum of 2 quarters · filed 2024-05-07 | $2.47M derived: sum of 3 quarters · filed 2024-05-07 | |
| 2022-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $1.37M derived: sum of 2 quarters · filed 2024-03-20 | $1.59M 10-K · filed 2024-03-20 | |
| 2022-09-30 | $332.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $545.00K 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $213.00K 10-Q · filed 2023-08-08 |